Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.
Investing Offers a Free Lunch, Says This Wall Street Veteran. Take It.
George Gatch, CEO of J.P. Morgan Asset Management, advises clients to diversify their holdings and stay in the market.
QQQI: This Is One Of The Best Constructed Income Funds For 2025
High Income ETF (QQQI) offers stable income with consistent payouts and strong returns in any market environment. See more ...
Early Retiree in 50s Living Off Dividends Shares His Top 7 Stock Picks — 'I Make Sure to Diversify for Risk'
Markets are headed for more volatility amid President Donald Trump's tariffs on Canada, China and Mexico and the potential response from the three countries. Investors are expected to turn to dividend ...
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
Suppose you want to diversify stock-specific risk by buying exchange-traded funds (ETFs), which hold multiple positions in ...
DIVO: It's Hard To Stand Out In Today's Market
The Amplify CWP Enhanced Dividend Income ETF offers a unique strategy combining dividend growth stocks with a tactical ...
news.stocktradersdaily5d
(JEPI) Trading Advice
Trading Advice for Jpmorgan Equity Premium Income Etf JEPI including day trading swing trading and long term investing plans ...
Dividend Investing in Canada: Trends, Leaders, and ETF Picks
Detailed price information for JPM Equity Premium Income ETF (JEPI-A) from The Globe and Mail including charting and trades.
CIBC Launches German CDR Suite to Bring European Stocks to Canadian Investors
Detailed price information for JPM Equity Premium Income ETF (JEPI-A) from The Globe and Mail including charting and trades.